Transgenic animals as models for human diseasereport of an EC Study Group

R LATHE, John Mullins

Research output: Contribution to journalArticlepeer-review

Abstract

This report results from the discussion of an Expert Group convened in Edinburgh on 29-30 October 1992 for a workshop on that subject sponsored and organized by the Commission of the European Communities, Directorate General XII (CEC-DG XII). The experts taking part in the workshop were: R. Lathe and J.J. Mullins, Coordinators (AFRC Centre for Genome Research, University of Edinburgh); G.N. Fracchia, Secretary (Medical Research-Pharmaceuticals, CEC-DG XII, Brussels); and the participants: C. Babinet (Dept d'Immunologie, Institut Pasteur, Paris); P. Eliard (EFPIA, Brussels); C. Benoist (LGME du CNRS/INSERM, Strasbourg); G. Bianchi (Ospedale San Raffaele, Universita di Milano, Milan); E. Boncinelli (DIBIT, Ospedale San Raffaele, Milan); G. Brem (Universitat Munchen); G. Cossu (Institute of Histology, School of Medicine, University of Rome); N. Dillon (MRC National Institute for Medical Research, London); V. Episkopou (Dept of Biochemistry & Molecular Genetics, St Mary's Hospital Medical School, London); M. Evans (Wellcome/CRC Institute, Cambridge); R. Forster (Italfarmaco Research Centre, Cinisello Balsamo, Milan); D. Ganten (Max-Delbruck-Zentrum fur Molekulare Medizin, Berlin); A. Gossler (Max-Delbruck-Laboratorium in der Max-Planck-Gesellschaft, Koln); J. Gray (Dept Psychology, Institute of Psychiatry, London); R. Hammer (Howard Hughes Medical Institute, University of Texas, Dallas, USA); A. Hobden (Genetics Unit, Glaxo Group Research Ltd, Middlesex); G. Kollias (Laboratory of Molecular Genetics, Hellenic Pasteur Institute, Athens); D. Lamy (Transgene SA, Strasbourg); D. Lincoln (MRC Reproductive Biology Unit, Edinburgh); J. Mallet (CNRS/LNCM, Gif-sur-Yvette); D. Melton (ICMB, University of Edinburgh, Edinburgh); J.M. Moalic (U127 INSERM, Hopital Laraboisire, Paris); S. Mockrin (Dept Health & Human Services, National Institutes of Health, Bethesda, MA, USA); J. Ottesen (Biopharmaceuticals Division, Dept of Gene Technology and Virology, Novo Industrie, Denmark); D. Porteous (MRC Human Genetics Unit, Western General Hospital, Edinburgh); P. Rae (Pharmaceutical Division, Miles, West Haven, USA); F. Theuring (Schering AG, Pharmaceutical Research, Berlin); G. Tremp (Rhone-Poulenc Rorer SA, Centre de Recherche de Vitry-Alfortville, Vitry-sur-Seine); H. Van der Putten (Dept Biotechnology, Ciba-Geigy AG, Basel); R. Wolf (ICRF Molecular Pharmacology Group, Biochemistry Dept, Edinburgh). Further supporting documentation and commentary were received from P. Dement (Amsterdam), U. Habenicht (Berlin), P. Gruss (Gottingen), M. Lyon (Oxford), C.C.J. Miller (London), W.-D. Schleuning (Berlin) and R. Williamson (London) and their contributions are gratefully acknowledged.

This paper is an edited compilation of texts prepared on each sub-topic by the rapporteurs. The content of this publication reflects the opinion of the Study Group, and not necessarily the official views of the institutions of the Community.

Original languageEnglish
Pages (from-to)286-299
Number of pages14
JournalTransgenic Research
Volume2
Issue number5
DOIs
Publication statusPublished - Sep 1993

Keywords

  • somatic gene therapy
  • DNA microinjection
  • viral vectors
  • pluripotent embryonic cells
  • human disease

Fingerprint

Dive into the research topics of 'Transgenic animals as models for human diseasereport of an EC Study Group'. Together they form a unique fingerprint.

Cite this